このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Clinical Evaluation of Hearing Aid OTC Self-Assessment Methods for Adults With Perceived Mild-to-Moderate Hearing Loss

2026年7月30日 更新者:Rehear Audiology Company LTD

Clinical Evaluation of Two Rehear RH210 Self-Assessment Methods for Generating NAL-R-Based Prescribed Gain Compared With Conventional Audiometry in Adults With Perceived Mild-to-Moderate Hearing Loss

The goal of this clinical trial is to compare two methods of self assessment of hearing with conventional audiometry in an OTC Hearing Aid for adults with perceived mild to moderate hearing loss. The main questions it aims to answer are:

  1. To evaluate agreement between prescribed gain outputs generated from conventional audiometry and those generated from the self-assessment response method.
  2. Determine whether either self-assessment response method provides acceptable estimated audibility.
  3. Evaluate participant preference between the detection response method and the audibility-release response method.

Researchers will compare the two novel methods with conventional audiometry to determine levels of agreement.

Participants will self assess their hearing methods using two novel methods of hearing assessment as well as receive a conventional audiometric evaluation of hearing levels.

調査の概要

詳細な説明

The purpose of this clinical investigation is to evaluate two RH210 hearing aid software self-assessment response methods used to generate NAL-R-based prescribed gain for adults with perceived mild-to-moderate hearing loss. The study will compare prescribed gain outputs derived from each RH210 self-assessment response method with prescribed gain outputs derived from conventional audiometry using the same NAL-R prescription approach. The study will also assess whether the resulting prescribed gain provides estimated audibility using Speech Intelligibility Index (SII) analysis, and will evaluate participant preference between the two self-assessment response methods. The RH210A is an air-conduction hearing aid designed for adults with perceived mild-to-moderate sensorineural hearing loss.

The two RH210 self-assessment response methods evaluated in this study are:

  1. Detection response method (Option 1): the participant presses a response control when they hear the tone or beep.
  2. Audibility-release response method (Option 2): the participant maintains a press while the tone or beep is audible and releases the response control when they no longer hear it.

The study is designed to:

  1. Evaluate agreement between NAL-R prescribed gain outputs generated from conventional audiometry and NAL-R prescribed gain outputs generated from each RH210 self-assessment response method.
  2. Compare the detection response method and audibility-release response method with respect to prescribed gain agreement by ear and frequency.
  3. Assess estimated audibility associated with the self-assessment-derived NAL-R prescriptions using Speech Intelligibility Index (SII) analysis.
  4. Determine whether either self-assessment response method provides acceptable estimated audibility, including in cases where prescribed gain does not exactly match the conventional-audiometry-derived NAL-R prescription.
  5. Evaluate participant preference between the detection response method and the audibility-release response method.
  6. Assess general agreement, completeness, invalid-test rate, usability and response consistency for each self-assessment response method.
  7. Support validation of the Rehear assessment-to-fitting pathway without positioning the RH210 self-assessment function as a diagnostic audiometer.

This study is not intended to establish Human Factors performance. However, observations arising during execution of the assessment workflow may identify opportunities to improve the user interface, workflow or user guidance before the final Human Factors validation study. These observations are exploratory development outputs and are not formal study endpoints.

研究の種類

介入

入学 (推定)

24

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:Sanna Hou, Master of Audiology
  • 電話番号:+61 2 9412 6872
  • メール:sann.hou@nal.gov.au

研究場所

    • New South Wales
      • Macquarie Park、New South Wales、オーストラリア、2113
        • National Acoustic Laboratories
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Age 18 years
  • Self-perceived mild-to-moderate hearing difficulties/ hearing loss
  • Competent smartphone use (able to complete self-fitting via the app)
  • Able and willing to provide informed consent
  • HHIA screening consistent with perceived hearing difficulty
  • Willingness and ability to attend two in-person research appointments
  • Ability to operate a SmartPhone

Exclusion Criteria:

  • Conductive or mixed hearing loss
  • Occluding cerumen
  • Otologic disease/ active ear pathology
  • Severe or profound hearing loss (PTA >S0dBHL) (WHO, 2021)
  • Presence of (red-flag) conditions relevant to OTC hearing aid use (per 21 CFR 801.421)
  • Visible deformity of the ear (congenital or traumatic).
  • Fluid, pus, or blood coming from the ear (e.g., active drainage).
  • Sudden or rapidly progressive hearing loss within the recent past (often defined as within ~90 days).
  • Any acute or chronic dizziness or vertigo associated with hearing issues.
  • Pain or discomfort in or around the ear.
  • Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
  • Unilateral hearing loss of sudden onset or large asymmetry between ears.
  • Audiometric air-bone gap suggestive of possible conductive pathology (e.g., gap equal or more than 15 dB at key frequencies)
  • Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
  • Unilateral hearing loss of sudden onset or large asymmetry between ears

Exclusion Criteria:

-

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Conventional manual pure-tone audiometry
The comparator for this clinical investigation is conventional manual pure-tone audiometry performed in accordance with ANSI/ASA S3.21-2004 (R2023), Methods for Manual Pure-Tone Threshold Audiometry, followed by generation of a NAL-R-based prescribed gain output.
実験的:Mode A
RH210 self-test method 1: detection response method, where the participant presses when they hear the tone or beep

The Investigational Medical Device (IMD) consists of the RH210 hearing aid software self-test function accessed through the Rehear smartphone application and used in combination with the RH210A compatible in-ear hardware platform.

For this clinical investigation, the RH210A hardware platform is used to present calibrated test sounds (pure tones) to the participant during the app-based self-test. The RH210A is not being evaluated as a diagnostic audiometer, and the study is not designed to evaluate the hearing aid's amplification performance.

The two RH210 self-test response methods evaluated in this study are:

  • Detection response method: the participant presses the response control when they hear the tone or beep (Mode A).
  • Audibility-release response method: the participant maintains the response control while the tone or beep is audible and releases the response control when they no longer hear the tone or beep (Mode B).
実験的:Mode B
RH210 self-test method 2: audibility-release response method, where the participant releases the response control when they no longer hear the tone or beep

The Investigational Medical Device (IMD) consists of the RH210 hearing aid software self-test function accessed through the Rehear smartphone application and used in combination with the RH210A compatible in-ear hardware platform.

For this clinical investigation, the RH210A hardware platform is used to present calibrated test sounds (pure tones) to the participant during the app-based self-test. The RH210A is not being evaluated as a diagnostic audiometer, and the study is not designed to evaluate the hearing aid's amplification performance.

The two RH210 self-test response methods evaluated in this study are:

  • Detection response method: the participant presses the response control when they hear the tone or beep (Mode A).
  • Audibility-release response method: the participant maintains the response control while the tone or beep is audible and releases the response control when they no longer hear the tone or beep (Mode B).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Agreement of NAL-R prescribed gain outputs (dB) between the comparator conditions
時間枠:Day 1

The primary endpoint is the agreement of NAL-R prescribed gain outputs (dB), by ear (R/L) and frequency (Hz), between:

  • Conventional-audiometry-derived NAL-R prescribed gain (dB), and
  • RH210 self-test-derived NAL-R prescribed gain (dB), generated using each of the two RH210 response methods.

The frequency-specific analysis will include: 500 Hz; 1 kHz; 2 kHz; and 4 kHz.

The two RH210 response methods are:

  • Detection response method: participant presses when they hear the tone or beep (Mode A).
  • Audibility-release response method: participant releases the response control when they no longer hear the tone or beep Mode B).
Day 1

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants with Treatment-Related Adverse Events as classified by ISO14155:2026
時間枠:Day 1

The secondary safety objective is to assess the safety of participant exposure to the RH210 app-based self-test procedure when the RH210A in-ear hardware platform is used to present test sounds.

Safety will be assessed by the incidence, severity, seriousness and relationship to the investigational device or study procedure of:

  • adverse events;
  • adverse device effects;
  • anticipated adverse device effects;
  • discomfort associated with in-ear device use;
  • excessive loudness or sound intolerance;

No formal statistical hypothesis is proposed for safety. Safety outcomes will be summarized descriptively.

Day 1
Difference in Speech Intelligibility Index (SII) and SRT in quiet (CNC words) between the three conditions
時間枠:Day 1

The secondary objective is to evaluate whether RH210 self-test-derived NAL-R prescribed gain outputs (dB) provide estimated audibility comparable to the conventional-audiometry-derived NAL-R reference pathway.

The secondary endpoint is the difference in Speech Intelligibility Index / Audibility Index and SRT in quiet between:

(1) The conventional-audiometry-derived NAL-R prescribed gain condition (dB); and (2) Each RH210 self-test-derived NAL-R prescribed gain (dB) condition.

The analysis will be conducted under a pre-specified standard aided speech condition (SRT50% dB), for example adaptive speech in quiet SRT50, with the final method defined in the Statistical Analysis Plan

Day 1

その他の成果指標

結果測定
メジャーの説明
時間枠
Participant preference (A vs B questionnaire) will be assessed after completion of both self fit response methods.
時間枠:Day 1

The first exploratory objective is to evaluate participant preference between the two RH210 self-test response methods.

Participant preference will be assessed after completion of both RH210 response methods. The endpoint will include:

  • proportion of participants preferring the detection response method;
  • proportion preferring the audibility-release response method;
  • proportion reporting no preference;
  • reasons for preference, where collected. No formal hypothesis is proposed. Results will be summarized descriptively.
Day 1
Compare the practical performance of the two RH210 self-test response methods using NAL checklist.
時間枠:Day 1

Exploratory endpoints will include, for each response method:

  • completion rate;
  • invalid or unusable test rate;
  • missing frequency-specific data rate;
  • test duration;
  • participant-reported ease of use;
  • observed difficulty or need for clarification;
  • repeatability or response consistency, where repeat data are available.

No formal hypothesis is proposed. Results will be summarized descriptively.

Day 1

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Bettina Turnbull, Doctor of Audiology、National Acoustic Laboratories

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月15日

一次修了 (推定)

2026年10月1日

研究の完了 (推定)

2026年10月1日

試験登録日

最初に提出

2026年7月26日

QC基準を満たした最初の提出物

2026年7月26日

最初の投稿 (実際)

2026年7月31日

学習記録の更新

投稿された最後の更新 (実際)

2026年8月3日

QC基準を満たした最後の更新が送信されました

2026年7月30日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

The study is a commercial sponsor investigation of a product that is not yet cleared by regulatory agencies

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する